After finishing at $14.51 in the prior trading day, Avidity Biosciences Inc (NASDAQ: RNA) closed at $15.31, up 5.51%. In other words, the price has increased by $+0.80 from its previous closing price. On the day, 1440504 shares were traded.
Ratios:
Our goal is to gain a better understanding of RNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.40 and its Current Ratio is at 11.40. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On March 31, 2023, Evercore ISI Downgraded its rating to In-line which previously was Outperform but kept the price unchanged to $20.
On July 20, 2022, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $29.Chardan Capital Markets initiated its Buy rating on July 20, 2022, with a $29 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 22 when Boyce Sarah sold 5,092 shares for $10.13 per share. The transaction valued at 51,582 led to the insider holds 44,008 shares of the business.
Flanagan W. Michael sold 4,129 shares of RNA for $41,827 on Jan 22. The CSTO now owns 35,871 shares after completing the transaction at $10.13 per share. On Jan 22, another insider, McCarthy Teresa, who serves as the Chief Human Resources Officer of the company, sold 2,065 shares for $10.13 each. As a result, the insider received 20,918 and left with 17,035 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 1.22B and an Enterprise Value of 685.43M. For the stock, the TTM Price-to-Sale (P/S) ratio is 111.88 while its Price-to-Book (P/B) ratio in mrq is 2.19. Its current Enterprise Value per Revenue stands at 67.62 whereas that against EBITDA is -3.18.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $25.38, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is 11.19, while the 200-Day Moving Average is calculated to be 9.14.
Shares Statistics:
The stock has traded on average 1.47M shares per day over the past 3-months and 758.32k shares per day over the last 10 days, according to various share statistics. A total of 69.77M shares are outstanding, with a floating share count of 65.82M. Insiders hold about 11.18% of the company’s shares, while institutions hold 100.35% stake in the company. Shares short for RNA as of Jan 31, 2024 were 7.64M with a Short Ratio of 5.20, compared to 9.83M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 9.62% and a Short% of Float of 9.74%.
Earnings Estimates
Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.66 for the current quarter, with a high estimate of $0.07 and a low estimate of -$0.88, while EPS last year was -$0.88. The consensus estimate for the next quarter is -$0.83, with high estimates of -$0.67 and low estimates of -$0.93.
Analysts are recommending an EPS of between -$1.88 and -$3 for the fiscal current year, implying an average EPS of -$2.74. EPS for the following year is -$3.51, with 6 analysts recommending between -$2.84 and -$3.9.
Revenue Estimates
6 analysts predict $12.21M in revenue for the current quarter. It ranges from a high estimate of $62.67M to a low estimate of $1.5M. As of the current estimate, Avidity Biosciences Inc’s year-ago sales were $2.77M, an estimated increase of 341.00% from the year-ago figure.
A total of 6 analysts have provided revenue estimates for RNA’s current fiscal year. The highest revenue estimate was $70.03M, while the lowest revenue estimate was $8.9M, resulting in an average revenue estimate of $19.59M. In the same quarter a year ago, actual revenue was $9.22M, up 112.40% from the average estimate.
